vs

Side-by-side financial comparison of Avidity Biosciences, Inc. (RNA) and Sunlands Technology Group (STG). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $10.1M, roughly 1.2× Sunlands Technology Group). Sunlands Technology Group runs the higher net margin — 24.0% vs -1398.3%, a 1422.3% gap on every dollar of revenue. Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 0.6%).

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

STG Partners, LLC (STG) is an American private equity firm and based in Menlo Park, California. Its predecessor, Symphony Technology Group ("Symphony") was founded in 2002 by Romesh Wadhwani, William Chisholm, and Bryan Taylor. In 2017, Symphony was reorganized as STG Partners. As of March 2025, STG Partners managed approximately $12 billion in 19 pooled investment vehicle for its clients. The firm itself has less than one billion dollars in assets.

RNA vs STG — Head-to-Head

Bigger by revenue
RNA
RNA
1.2× larger
RNA
$12.5M
$10.1M
STG
Higher net margin
STG
STG
1422.3% more per $
STG
24.0%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
0.6%
STG

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
RNA
RNA
STG
STG
Revenue
$12.5M
$10.1M
Net Profit
$-174.4M
$2.4M
Gross Margin
88.5%
Operating Margin
-1513.5%
26.5%
Net Margin
-1398.3%
24.0%
Revenue YoY
434.0%
Net Profit YoY
-117.0%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RNA
RNA
STG
STG
Q3 25
$12.5M
$10.1M
Q2 25
$3.8M
$9.3M
Q1 25
$1.6M
Q4 24
$3.0M
$9.7M
Q3 24
$2.3M
Q2 24
$2.0M
$10.0M
Q1 24
$3.5M
Q4 23
$2.2M
Net Profit
RNA
RNA
STG
STG
Q3 25
$-174.4M
$2.4M
Q2 25
$-157.3M
$1.4M
Q1 25
$-115.8M
Q4 24
$-102.3M
$1.8M
Q3 24
$-80.4M
Q2 24
$-70.8M
$2.2M
Q1 24
$-68.9M
Q4 23
$-60.4M
Gross Margin
RNA
RNA
STG
STG
Q3 25
88.5%
Q2 25
85.2%
Q1 25
Q4 24
83.3%
Q3 24
Q2 24
85.2%
Q1 24
Q4 23
Operating Margin
RNA
RNA
STG
STG
Q3 25
-1513.5%
26.5%
Q2 25
-4448.7%
15.2%
Q1 25
-8360.9%
Q4 24
-4069.6%
13.4%
Q3 24
-4200.9%
Q2 24
-4040.4%
Q1 24
-2178.6%
Q4 23
-3043.5%
Net Margin
RNA
RNA
STG
STG
Q3 25
-1398.3%
24.0%
Q2 25
-4089.3%
15.4%
Q1 25
-7360.0%
Q4 24
-3439.5%
18.2%
Q3 24
-3441.7%
Q2 24
-3461.8%
21.5%
Q1 24
-1943.4%
Q4 23
-2756.2%
EPS (diluted)
RNA
RNA
STG
STG
Q3 25
$-1.27
Q2 25
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$-0.65
$0.31
Q1 24
$-0.79
Q4 23
$-0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RNA
RNA
STG
STG
Cash + ST InvestmentsLiquidity on hand
$350.2M
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$17.7M
Total Assets
$2.1B
$41.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RNA
RNA
STG
STG
Q3 25
$350.2M
$15.1M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
$15.6M
Q3 24
$370.2M
Q2 24
$575.8M
$18.7M
Q1 24
$471.4M
Q4 23
$185.1M
Total Debt
RNA
RNA
STG
STG
Q3 25
Q2 25
Q1 25
Q4 24
$1.5M
Q3 24
Q2 24
$1.8M
Q1 24
Q4 23
Stockholders' Equity
RNA
RNA
STG
STG
Q3 25
$1.9B
$17.7M
Q2 25
$1.2B
$12.6M
Q1 25
$1.3B
Q4 24
$1.4B
$10.7M
Q3 24
$1.5B
Q2 24
$1.2B
$7.6M
Q1 24
$830.9M
Q4 23
$500.8M
Total Assets
RNA
RNA
STG
STG
Q3 25
$2.1B
$41.2M
Q2 25
$1.4B
$40.3M
Q1 25
$1.5B
Q4 24
$1.6B
$42.4M
Q3 24
$1.6B
Q2 24
$1.3B
$41.3M
Q1 24
$951.5M
Q4 23
$628.6M
Debt / Equity
RNA
RNA
STG
STG
Q3 25
Q2 25
Q1 25
Q4 24
0.14×
Q3 24
Q2 24
0.24×
Q1 24
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RNA
RNA
STG
STG
Operating Cash FlowLast quarter
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RNA
RNA
STG
STG
Q3 25
$-156.2M
Q2 25
$-199.7M
Q1 25
$-124.8M
Q4 24
$-99.9M
Q3 24
$-65.6M
Q2 24
$-65.0M
Q1 24
$-70.4M
Q4 23
$16.5M
Free Cash Flow
RNA
RNA
STG
STG
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
Q4 23
$15.6M
FCF Margin
RNA
RNA
STG
STG
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Q4 23
713.1%
Capex Intensity
RNA
RNA
STG
STG
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Q4 23
39.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons